戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ent (aspirin/clopidogrel vs aspirin/placebo; double-blinded).
2  and 2, allocation to DSM265 and placebo was double-blinded.
3 ients were assigned via central computerized double-blind 1:1 randomization to receive either a singl
4                We did a phase 2, randomised, double-blind, active-controlled, non-inferiority study.
5                          In this randomised, double-blind, active-controlled, phase 3 equivalence tri
6 vs pravastatin for Dyslipidemia) randomised, double-blind, active-controlled, phase 4 trial (INTREPID
7 nters were randomized (1:1 ratio) to receive double-blind adjunctive safinamide or placebo for 24 wee
8                                     We did a double-blind, allocation concealed, randomised, placebo-
9 ients completed study drug dosing during the double-blind and open-label phases, respectively.
10                                         This double-blind and placebo (or low-dose)-controlled random
11      We approached this question by applying double-blind bihemispheric transcranial direct current s
12                                  Randomized, double-blind clinical trial comparing oral cephalexin an
13            A randomized, placebo-controlled, double-blind clinical trial conducted in Isala Zwolle, t
14                    We conducted a randomized double-blind clinical trial in adults with NDD-CKD and i
15 atment of actinic keratosis in a randomized, double-blind clinical trial involving 131 participants.
16                  The use of a placebo and of double-blind control groups in surgery CTs would improve
17                            A new randomized, double-blind controlled study has found that playing a v
18 a secondary analysis of MS-STAT, a 24-month, double-blind, controlled trial of patients with SPMS don
19 PAM JNJ-39393406 (100 mg b.i.d.) or placebo (double-blind, counter-balanced).
20                               We performed a double-blind crossover challenge of 59 individuals on a
21  a novel endogenous pathway.In a randomized, double-blind crossover study, 16 healthy individuals wer
22 , ascending dose cohorts underwent a further double-blind crossover, placebo-controlled oral gluten c
23                          In this randomized, double-blind, crossover study, twelve normoglycaemic men
24     We did a randomised, placebo-controlled, double-blind, crossover trial of a quadpill-a single cap
25 ealthy male subjects completed a randomized, double-blinded, crossover-design study in which they con
26 ment with 20 mg vortioxetine or placebo in a double-blind design.
27                             METHODS AND In a double-blinded design, 40 patients with moderate-severe
28 e conducted two phase 1, placebo-controlled, double-blind, dose-escalation trials of an rVSV-based va
29                         In this single-site, double-blind, double-dummy clinical trial, we randomly a
30 osed Triple Therapy) trial was a randomized, double-blind, double-dummy study comparing 24 weeks of o
31                                      In this double-blind, double-dummy trial, we enrolled post-menop
32           In this international, randomised, double-blind, double-dummy, phase 3 trial, we recruited
33                We undertook this randomised, double-blind, efficacy, immunogenicity, and safety study
34 erlands, and Sweden), with optional 12-month double-blind extensions.
35 s (n=7513) were randomized in a double-dummy double-blind fashion to either extended-duration oral be
36 l maintenance doses of 300 or 3000 mg/d in a double-blinded fashion.
37 which was defined as the negativization of a double-blind food challenge results at 12, 24, and 36 mo
38 2 randomized, crossover, controlled studies (double-blinded for the supplements), each on 16 healthy
39                               We conducted a double-blind, household-cluster-randomized, placebo-cont
40 ts with mild-to-moderate AD in a randomized, double-blind, intraindividual comparison of 3 approved a
41 tients were randomized equally to receive 15 double-blind intravenous infusions of adjunctive lanicem
42 :1 using an interactive response system to a double-blind investigational product, and stratified by
43 men and >/=6 mg/dl in women) randomized in a double-blinded manner to receive placebo or allopurinol
44                             This randomized, double-blind, multicenter study evaluated the effects of
45                   We conducted a randomized, double-blind, multicenter trial of RIV4 (45 mug of recom
46                                 Prospective, double-blind, multicenter, randomized controlled study.
47                                      In this double-blind, multicenter, randomized, parallel-group st
48                         We did a randomised, double-blind, multicentre phase 2 trial of a combination
49                             This randomised, double-blind, multicentre, phase 3 trial was done in 87
50                          In this randomised, double-blind, multicentre, placebo-controlled, non-infer
51                                     We did a double-blind, multicentre, placebo-controlled, randomise
52  Pancreatic Cancer (ViP) trial was a phase 2 double-blind, multicentre, randomised placebo-controlled
53                                      In this double-blind, multicentre, randomised trial (GEMINI-ACS-
54                                      In this double-blind, multicentre, randomised, placebo-controlle
55                             This randomised, double-blind, multiperiod, phase 3 trial was done at 38
56                        METHOD: In a 16-week, double-blind, multisite comparison study, 142 participan
57                                A randomized, double-blind, multisite placebo-controlled trial conduct
58  with meropenem in a multinational, phase 3, double-blind, non-inferiority trial (REPROVE).
59                 In this phase 3, randomised, double-blind, non-inferiority trial, patients from 185 e
60                          In a single-center, double-blind, noninferiority trial involving adults with
61                    METHOD: In an exploratory double-blind parallel-group trial, patients with schizop
62                            This was a 12-mo, double-blind, parallel design, placebo-controlled, rando
63 ge intestinal mucosa in humans.A randomized, double-blind, parallel-design trial was conducted in 38
64 iDiet was a 24-month randomised, controlled, double-blind, parallel-group, multicentre trial (11 site
65                          In this randomised, double-blind, parallel-group, phase 3 trial done at 152
66                                     For this double-blind, parallel-group, randomised, controlled tri
67                               Single-center, double-blind, parallel-group, randomized clinical trial
68                 This randomised, controlled, double-blind, parallel-group, superiority trial was done
69 nting 4,029 [alirocumab] and 2,114 [control] double-blind patient-years' exposure).
70  I disorder (6.3% compared with 1.6%) in the double-blind period.
71 zed to asenapine or placebo treatment in the double-blind period.
72 e to recurrence of any mood event during the double-blind period.
73 le-blind phase for 8 weeks and a randomised, double-blind phase (parts 1 and 2, reported here) for 12
74 1666 patients randomized into 1 of 5 12-week double-blind phase 2 parent studies completed a parent s
75           ASPIRE consisted of an open-label, double-blind phase for 8 weeks and a randomised, double-
76 olerated, with similar adverse events in the double-blind phase to placebo.
77                                   During the double-blind phase, five (33%) patients assigned to BIIB
78 1.9%) discontinued from the study during the double-blind phase.
79  received DBS implantation and completed the double-blind phase.
80 ere reported in the BIIB074 group during the double-blind phase.
81 to BIIB074 or placebo for up to 28 days in a double-blind phase.
82 om baseline) averaged over months 4-6 of the double-blind phase.
83      In this randomised, regimen-controlled, double-blind, phase 2 trial, we enrolled adult patients
84                          In this randomised, double-blind, phase 2 trial, we recruited patients aged
85      In this randomised, placebo-controlled, double-blind, phase 2 trial, women aged 18 years or olde
86                          In this randomized, double-blind, phase 3 study, we assigned 3396 patients w
87                         We did a randomised, double-blind, phase 3 trial in patients with advanced or
88 this 6-month randomized, placebo-controlled, double-blind, phase 3 trial, we randomly assigned 395 pa
89                          In this randomised, double-blind, phase 3 trial, we recruited patients aged
90                          In this randomised, double-blind, phase 3b trial, we enrolled adults aged 18
91                  ORAL Strategy was a 1 year, double-blind, phase 3b/4, head-to-head, non-inferiority,
92        Patients and Methods This randomized, double-blind, phase III study enrolled patients with his
93    Patients and Methods In this multicenter, double-blind, phase III trial, patients were randomly as
94 tly greater reduction from baseline than the double-blind placebo in the NRS (-23%, 95% CI -45 to -1;
95 gnetic resonance imaging (fMRI) in a 2-drug, double-blind placebo-controlled crossover design conduct
96                                         In a double-blind placebo-controlled crossover design, the im
97                                 METHOD: In a double-blind placebo-controlled design, 46 unmedicated d
98  capture and report clinical observations in double-blind placebo-controlled food challenges (DBPCFC)
99                           In Experiment 1, a double-blind placebo-controlled pharmacology study, we m
100 mg daily or matching placebo in a randomised double-blind placebo-controlled phase.
101 stemic allergen-specific IgE, we performed a double-blind placebo-controlled pilot trial in which bir
102  Infants born to women who participated in a double-blind placebo-controlled RCT in 2011 and 2012 on
103                              In a randomized double-blind placebo-controlled study, 56 patients with
104 alyzed data from 1092 patients enrolled in a double-blind placebo-controlled trial to evaluate the ef
105       Purpose To determine, in a multicenter double-blinded placebo-controlled trial, whether maximal
106 including 12 patients; a phase 3 randomized, double blind, placebo controlled study involving 186 pat
107                                 (Randomized, Double-Blind, Placebo Controlled Study of the Short Term
108                                         In a double-blind, placebo-controlled between-subject design,
109 set of cord blood samples from a randomized, double-blind, placebo-controlled clinical trial (the Vit
110      We performed a multicenter, randomized, double-blind, placebo-controlled clinical trial.
111                                  Randomized, double-blind, placebo-controlled clinical trial.
112 f rural Bangladeshi children from 2 previous double-blind, placebo-controlled cluster-randomized tria
113                             In a randomized, double-blind, placebo-controlled crossover study of indi
114                   We performed a randomized, double-blind, placebo-controlled crossover study with si
115  kU/L for each food, or both, and a positive double-blind, placebo-controlled food challenge at 500 m
116 lication for 12 months, patients underwent a double-blind, placebo-controlled food challenge to estab
117 n 22 patients with peanut allergy undergoing double-blind, placebo-controlled food challenge to peanu
118 n = 221) had peanut sensitivity and positive double-blind, placebo-controlled food challenges to an e
119 allergy (secondary outcome) was confirmed by double-blind, placebo-controlled food challenges.
120                                       In two double-blind, placebo-controlled immunotherapy studies,
121 t study consists of a randomized, crossover, double-blind, placebo-controlled laboratory study of IBU
122     Patients originated from the randomized, double-blind, placebo-controlled OmegAD study, in which
123 onducted in the United States, followed by a double-blind, placebo-controlled part B in East Africa.
124                     To this end, we combined double-blind, placebo-controlled pharmacology [D2 recept
125             In this multicentre, randomised, double-blind, placebo-controlled phase 2 study (BERIL-1)
126                          In this randomised, double-blind, placebo-controlled phase 2 study, we enrol
127           In this single-centre, randomised, double-blind, placebo-controlled phase 2 trial, healthy
128                         We did a randomised, double-blind, placebo-controlled phase 2b trial, compris
129 cacy in Nonmetastatic RCC) was a randomized, double-blind, placebo-controlled phase 3 clinical trial
130                                            A double-blind, placebo-controlled pilot trial assessed sa
131                         We did a randomised, double-blind, placebo-controlled pilot trial at a single
132                                              Double-blind, placebo-controlled randomized trial (April
133                                            A double-blind, placebo-controlled randomized trial with c
134                            This multicenter, double-blind, placebo-controlled RCT was powered on a 5%
135 analysis of the results from the randomised, double-blind, placebo-controlled SIROCCO and CALIMA phas
136                             This randomized, double-blind, placebo-controlled study (TL7116958) was c
137                   A multicenter, randomized, double-blind, placebo-controlled study evaluated 3 regim
138                       In X-ACT, a phase III, double-blind, placebo-controlled study, CSU patients (18
139 that reduces chorea, was well tolerated in a double-blind, placebo-controlled study.
140 d, multicenter, prospective, 1:1 randomized, double-blind, placebo-controlled study.
141  magnetic resonance imaging to a randomized, double-blind, placebo-controlled trial (RCT) of antidepr
142                             This randomized, double-blind, placebo-controlled trial assessed the effe
143                          In this randomised, double-blind, placebo-controlled trial at 590 sites in 4
144      We performed our study as a randomized, double-blind, placebo-controlled trial by training other
145           METHODS AND TIME was a randomized, double-blind, placebo-controlled trial comparing 150 mil
146            Part 1 consisted of a randomised, double-blind, placebo-controlled trial done over 18 mont
147          We conducted a phase 2, randomized, double-blind, placebo-controlled trial in 27 centers acr
148             METHOD: This 6-week, randomized, double-blind, placebo-controlled trial included patients
149 nt Sertraline Trial (CAST) was a randomized, double-blind, placebo-controlled trial involving 201 pat
150                   We conducted a randomized, double-blind, placebo-controlled trial involving 27,564
151                   We conducted a randomized, double-blind, placebo-controlled trial involving 30,449
152      We conducted a multicenter, randomized, double-blind, placebo-controlled trial involving patient
153                   We conducted a randomized, double-blind, placebo-controlled trial of amitriptyline
154 esistance Intervention After Stroke trial, a double-blind, placebo-controlled trial of pioglitazone f
155                   We conducted a randomized, double-blind, placebo-controlled trial of pregabalin in
156                             This randomized, double-blind, placebo-controlled trial recruited patient
157 hysicians' Health Study II was a randomized, double-blind, placebo-controlled trial testing multivita
158  Vitamin D Assessment Study is a randomized, double-blind, placebo-controlled trial that recruited pa
159      This PreSERVE-AMI (Phase 2, randomized, double-blind, placebo-controlled trial) represents the l
160 n this prospective, multicenter, randomized, double-blind, placebo-controlled trial, 96 HT recipients
161         For this international, multicentre, double-blind, placebo-controlled trial, adult patients (
162             In this multicentre, randomised, double-blind, placebo-controlled trial, adults (>/=18 ye
163                          In this randomised, double-blind, placebo-controlled trial, adults with pred
164  of asthma, were included in the randomized, double-blind, placebo-controlled trial, comprising 3 yea
165           In this single-centre, randomised, double-blind, placebo-controlled trial, patients with mo
166                 In this phase 2, randomized, double-blind, placebo-controlled trial, we compared subc
167                          In this randomized, double-blind, placebo-controlled trial, we investigated
168                          In this randomised, double-blind, placebo-controlled trial, we randomly allo
169                         In this multicenter, double-blind, placebo-controlled trial, we randomly assi
170              In a preregistered, randomized, double-blind, placebo-controlled trial, we tested the ef
171  doxycyline in a pre-registered, randomised, double-blind, placebo-controlled trial.
172  were pooled from two phase III, randomized, double-blind, placebo-controlled trials of IFN-gamma-1b
173  Long-Term Therapy (XPORT) was a randomized, double-blind, placebo-controlled withdrawal study that i
174                   We conducted a randomized, double-blind, placebo-controlled, 24-week trial of imati
175                                 A randomized double-blind, placebo-controlled, 3-parallel-group study
176                                         In a double-blind, placebo-controlled, between-subject design
177 t functional magnetic resonance imaging in a double-blind, placebo-controlled, crossover design to de
178 hree time points in this baseline-corrected, double-blind, placebo-controlled, crossover study.
179          We conducted a phase I, randomized, double-blind, placebo-controlled, dose-escalating study
180                We did a phase 2, randomised, double-blind, placebo-controlled, dose-escalation trial
181 as examined in a 3-site, 8-week, randomized, double-blind, placebo-controlled, fixed-dose trial using
182                             This randomized, double-blind, placebo-controlled, multicenter study eval
183                We did a phase 3, randomised, double-blind, placebo-controlled, multicentre study (REG
184              This was a phase 2, randomised, double-blind, placebo-controlled, multicentre study of e
185                 In this phase 3, randomised, double-blind, placebo-controlled, multicentre study, pat
186          The BELLE-2 trial was a randomised, double-blind, placebo-controlled, multicentre study.
187        We conducted a phase 1b, multicenter, double-blind, placebo-controlled, multiple-ascending-dos
188         We conducted a phase 2, multicenter, double-blind, placebo-controlled, multiple-ascending-dos
189                          In this randomised, double-blind, placebo-controlled, non-inferiority trial,
190 rom 3 phase IIB and 4 phase IIIA randomized, double-blind, placebo-controlled, parallel group, multic
191                             In this 12-week, double-blind, placebo-controlled, parallel-group trial,
192             In this multicenter, randomized, double-blind, placebo-controlled, parallel-group trial,
193                         We did a randomised, double-blind, placebo-controlled, parallel-group, multic
194                       We did two randomised, double-blind, placebo-controlled, phase 1 studies at 12
195                     The study was a 12-week, double-blind, placebo-controlled, phase 2 trial of patie
196                             This randomised, double-blind, placebo-controlled, phase 2 trial was done
197              In the multicentre, randomised, double-blind, placebo-controlled, phase 3 FREEDOM trial,
198                This multicentre, randomised, double-blind, placebo-controlled, phase 3 study was done
199                             This randomised, double-blind, placebo-controlled, phase 3 trial (CONTINU
200      RADIANT-4 is a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial done in
201  Patients were eligible for this randomised, double-blind, placebo-controlled, phase 3 trial if they
202                                      In this double-blind, placebo-controlled, phase 3 trial, we rand
203                          In this randomised, double-blind, placebo-controlled, phase 3 trial, we recr
204                          In this randomised, double-blind, placebo-controlled, phase 3 trial, we recr
205                   We conducted a randomized, double-blind, placebo-controlled, phase 3, crossover tri
206                            This prospective, double-blind, placebo-controlled, phase IIb, parallel, f
207                                    A 4-year, double-blind, placebo-controlled, population-based rando
208                                              Double-blind, placebo-controlled, randomized clinical tr
209                                 METHOD: In a double-blind, placebo-controlled, randomized clinical tr
210 nical Trial), an international, multicenter, double-blind, placebo-controlled, randomized clinical tr
211                                  NEURAPRO, a double-blind, placebo-controlled, randomized clinical tr
212                                     Rigorous double-blind, placebo-controlled, randomized controlled
213                    A multinational, phase 3, double-blind, placebo-controlled, randomized withdrawal
214                               We conducted a double-blind, placebo-controlled, randomized, fixed-dose
215                    This phase 2, randomised, double-blind, placebo-controlled, single-centre, crossov
216                          Using a randomized, double-blind, placebo-controlled, within-subject crossov
217 motivation in 21 healthy human subjects in a double-blinded, placebo (saline)-controlled, cross-over
218 icipants with mild asthma were enrolled in a double-blinded, placebo-controlled crossover study to as
219                                            A double-blinded, placebo-controlled randomized clinical t
220                                              Double-blinded, placebo-controlled trial at 9 academic m
221 rican Region with Malaria) was a randomized, double-blinded, placebo-controlled trial conducted in ma
222                      METHODS AND Randomized, double-blinded, placebo-controlled trial enrolled 31 pat
223                 Patients and Methods In this double-blinded, placebo-controlled trial, patients with
224 ertiary HPS unit were randomly assigned in a double-blinded, placebo-controlled trial.
225                          In this randomised, double-blinded, placebo-controlled, multiregional trial
226                               We performed a double-blinded, placebo-controlled, parallel interventio
227                  In this 1-year, randomised, double-blinded, placebo-controlled, phase 3 study (LIBER
228                   METHODS AND We undertook a double-blind randomised controlled trial of small-quanti
229                                      In this double-blind randomised placebo-controlled trial, we enr
230                      This was a multicentre, double-blind, randomised placebo-controlled trial for wh
231                         In this multicentre, double-blind, randomised trial in seven Danish universit
232              In this phase 3, multinational, double-blind, randomised, controlled trial, adults (aged
233                               DEPICT-1 was a double-blind, randomised, parallel-controlled, three-arm
234             EORTC 18071 was a multinational, double-blind, randomised, phase 3 trial in patients with
235                                 The phase 2, double-blind, randomised, placebo-controlled MERIT-1 tri
236 ion study in a pilot safety cohort, we did a double-blind, randomised, placebo-controlled trial based
237                                     For this double-blind, randomised, placebo-controlled trial, we e
238                                We report two double-blind, randomised, placebo-controlled trials in a
239          We did this single-centre, 150-day, double-blind, randomised, placebo-controlled, crossover
240 out impeding other neutrophil functions in a double-blind randomized clinical trial in healthy elders
241         In vitro results were confirmed in a double-blind randomized clinical trial in healthy elders
242  E and Selenium (PREADViSE) trial began as a double-blind randomized clinical trial in May 2002, whic
243  Trials Group Symptom Control Trial SC.23, a double-blind randomized clinical trial that investigated
244 were eligible for inclusion if they were (1) double-blind randomized clinical trials of DCS as an aug
245                    The analysis included 167 double-blind randomized controlled trials with 28,102 ma
246 disease accrued between 2006 and 2010 to the double-blind randomized placebo-controlled phase 3 trial
247 nrolled 10 SCA38 patients, and carried out a double-blind randomized placebo-controlled study for 16
248                                   This was a double-blind randomized sham controlled pilot study of t
249 en-label period, of whom 253 enrolled in the double-blind randomized withdrawal period (127 in the pl
250 - to 16-week open-label period and a 26-week double-blind randomized withdrawal period.
251                                 Multicenter, double-blind, randomized clinical trial including 500 pa
252                        This parallel-design, double-blind, randomized clinical trial, called Resverat
253 up receiving a corn-soy blend.A prospective, double-blind, randomized controlled clinical trial was c
254                                         In a double-blind, randomized controlled trial, once-daily in
255                                         This double-blind, randomized crossover study addressed the i
256  intranasal oxytocin (24 IU) or placebo in a double-blind, randomized crossover study.
257  screened as anemic.In this 2 x 2 factorial, double-blind, randomized trial, nonpregnant women (aged
258                              This multisite, double-blind, randomized within-patient study was conduc
259                    We performed two similar, double-blind, randomized, 6-month phase 3 trials (Elaris
260                                         This double-blind, randomized, controlled trial investigates
261  mg (p.o.) and placebo over 2 test days in a double-blind, randomized, counterbalanced, cross-over de
262                                              Double-blind, randomized, crossover noninferiority trial
263 f latitude and skin color.In a longitudinal, double-blind, randomized, food-based intervention study,
264                                 Multicenter, double-blind, randomized, parallel-group, phase 3 equiva
265                               We conducted a double-blind, randomized, parallel-group, placebo-contro
266                    Therefore, we conducted a double-blind, randomized, placebo-controlled crossover t
267                         In this multicenter, double-blind, randomized, placebo-controlled study, 74 p
268              METHOD: A 12-week, prospective, double-blind, randomized, placebo-controlled trial (meth
269                         In this prospective, double-blind, randomized, placebo-controlled trial condu
270 ress existing knowledge gaps, we conducted a double-blind, randomized, placebo-controlled trial to in
271                         In this multicenter, double-blind, randomized, placebo-controlled trial, we a
272                                      Using a double-blind, randomized, placebo-controlled, parallel d
273                                      In this double-blind, randomized, placebo-controlled, phase 2 tr
274 ldren's Respiratory Initiative [TCRI]) and a double-blinded, randomized, controlled trial (MAKI), usi
275                  We conducted a prospective, double-blinded, randomized, placebo-controlled, crossove
276          Patients who completed the 24-month double-blind REFLEX (REbif FLEXible dosing in early MS)
277 ncephalic grafts as part of an NIH-sponsored double-blind sham-controlled trial.
278 ignificant difference in response during the double-blind, sham-controlled phase (12 [20%] patients i
279                                The trial was double-blinded; some unmasking took place at age 2 years
280                               We performed a double-blind study at 49 hospitals in Europe and Israel,
281 ER PFO Occluder to Medical Management) was a double-blind study investigating migraine characteristic
282           In a randomized placebo-controlled double-blind study of 162 HIV-negative RV144 vaccine rec
283              Phase 2 randomized, controlled, double-blinded study of 4 antiretroviral regimens used a
284                                  Randomized, double-blind, treat-to-target crossover trial including
285 ne days from baseline to the last 4 weeks of double-blind treatment (weeks 9-12).
286    Pooled data from 14 trials were analyzed (double-blind treatment 8 to 104 weeks; n = 3,340 alirocu
287 ion >/= 30% from baseline for >/= 50% of the double-blind treatment period, were observed in 20%, 44%
288  three times per day orally during a 12-week double-blind treatment period.
289 pose LUME-Meso is a phase II/III randomized, double-blind trial designed to assess efficacy and safet
290 , we conducted a single-center, prospective, double-blind trial of 39 patients with mucinous-type pan
291 first large, randomized, placebo-controlled, double-blind trial of a statin with standard-of-care for
292 ndred forty-six CAE children in a randomized double-blind trial of ethosuximide, lamotrigine, and val
293 were recruited for a randomized, controlled, double-blind trial of vitamin D supplementation in pregn
294                          In this randomized, double-blind trial, outpatients with schizophrenia (n=55
295                                         In a double-blind trial, patients were randomized to tolvapta
296                                      In this double-blind trial, we randomly assigned 2157 patients w
297 withdrawal, multicenter, placebo-controlled, double-blind trial.
298          This parallel group, semirandomized double-blinded trial was conducted in a single center in
299 at of a control.In a randomized, controlled, double-blinded trial, 220 participants aged 18-60 y with
300   Among women participating in a randomized, double-blinded trial, we assessed the effect of periodic

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。
 
Page Top